Get Healthy!

When it comes to coverage for the pricey GLP-1 weight-loss drugs Wegovy and Zepbound, only a fifth of large U.S. companies cover the medications in their health insurance plans, a new survey shows.

In a report published Wednesday in the journal Health Affairs, researchers also found that a third of compani...

Food left in the stomach or stool left in the bowel can impede a doctor's ability to successfully perform an endoscopy or colonoscopy.

Now, research finds this scenario is more likely if the patient is taking popular new weight-loss meds such as Ozempic

In a finding that suggests Ozempic and Wegovy have powers that extend beyond weight loss, a new study finds the medications might also lower people’s risk of opioid overdose.

People with type 2 diabetes prescribed semaglutide (Ozempic, Wegovy) had a significantly lower risk of an opioid OD t...

During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced tough questions over the company's high prices for its blockbuster drugs Ozempic and Wegovy.

While testifying before the Senate Committee on Health, Education, Labor and Pens...

Heavy-duty endurance exercise can cause body fat levels to drop without any accompanying weight loss, a new small-scale study indicates.

A group of eleven middle-aged men who cycled 710 miles in seven days lost only about 1% of their total weight, because they ate and drank enough to offset the calorie burn.

But they lost over 9% of their overall body fat, including a nearly 15% red...

Wegovy, Zepbound and other cutting-edge weight-loss drugs can be tough to get these days.

They’re in short supply, and often too expensive to afford without insurance coverage.

Because of these barriers, many people are doing an end-run around their doctor’s office, reaching out ...

Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP-1 medicines like Ozempic can help stop that.

In a new decades-long study, veterans with diabetes and what's known as metabolic dysfunction-associated steatotic liver disease (MASLD) were 14% less likely to progress t...

Ozempic and its weight-loss cousin, Wegovy, outperform another longstanding weight-loss drug that targets the same hormone associated with blood sugar and appetite, a new study finds.

Ozempic and Wegovy (semaglutide) promoted the loss of 10% or more body weight in 61% of people being treated for o...

Initially approved to treat type 2 diabetes, Ozempic and Mounjaro also can help people with type 1 diabetes lose weight and control their blood sugar levels, a new study finds.

Overweight or obese type 1 diabetics taking Mounjaro were able to reduce the amount of daily insul...

Statistics from 2023 on U.S. obesity rates bring no good news: In every state in the nation, 1 in every 5 people is now obese, the new tally shows.

In 2013, not one state had an adult obesity rate topping 35%, but 10 years later 23 states had achieved that dubious distinction, according to data ...

The injectable weight-loss drug Zepbound appears to work better in women than in men, according to a new analysis of the clinical trials that led to its approval.

All doses of tirzepatide consistently reduced weight in both women and men, researchers found.

But women lost up to 25% of their initial body weight when treated with ti...

Ozempic and Wegovy can prevent heart problems in overweight and obese people, particularly if they also suffer from kidney disease, a new clinical trial shows.

The drugs’ active ingredient, semaglutide, reduced heart health risk by 20% in heavyset people who took it for more than three years...

The weight-loss drug liraglutide helped obese children lower their BMI and reach a healthier weight, researchers report.

The findings, published Tuesday in the New England Journal of Medicine and presented simultaneously at the European Association for the Study of Diabetes annual meeting in Madrid, are the f...

An experimental weight-loss pill appears to help people quickly shed pounds, a new study says.

People who took the drug amycretin lost up to 13% of their body weight over three months, according to early clinical trial results presented at the European Association for the Study of Diabetes annual meeting in Madrid.

Amycretin mimics the action of two different hunger-related hormones...

Losing weight can help a person with obesity -- especially those with diabetes -- fend off serious infections, new data shows.

It's an important finding, since "up to one in three hospitalizations in people with diabetes are for infections and people with diabetes are twice as likely to be hospitalized with infections than the general population. They are also at high risk of readmission,...

A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of the weekly injections they now take, a new study demonstrates.

The new formulation encases semaglutide in a hydrogel that slowly releases the drug as the gel dissolves, researchers...

The booming popularity of the weight-loss drug semaglutide has prompted increasing concerns about potential side effects from taking Ozempic or Wegovy.

But a new study rules out one possible problem -- using semaglutide does not increase a person&rsq...

Folks taking weight-loss drugs like Wegovy or Zepbound might think they’ve found a shortcut to better health.

But they still need to eat a high-quality diet if they want to maintain their well-being while they shed pounds, says a doctor with ...

New trials are showing how the blockbuster diabetes and weight-loss meds Ozempic and Wegovy can boost health in even more ways.

These two injected drugs are versions of semaglutide. In multiple new data analyses, the drugs appeared to cut people's odds for heart failure and its complications, reduce deaths from COVID-19 and lower deaths...

Breastfeeding helps women shed those extra pounds of "pregnancy weight," a new study finds, and the effect is even more pronounced for moms who were overweight before their pregnancy.

Among women who exclusively breastfed their baby during its first year, women who were normal weight prior to pregnancy lost weight, but still retained about three extra pounds of their pregnancy weight, re...

New Medicare rules could make 3.6 million Americans -- or even more -- eligible for treatment with the pricey weight-loss drug Wegovy, a new study finds.

Under the new rules, the government will pay for Wegovy treatment if a person with high BMI also has heart disease.

Until now, federal reg...

A study of more than 400,000 people tracked for up to 24 years finds that those who got their dietary fat from plants versus animals had significantly lower odds of dying during the study period.

Plant-based fats' benefit included a reduced odds for deaths due to heart disease, the research showed.

Conversely, the study "provides evidence that diets high in animal-based fats, includ...

WEDNESDAY, Aug. 7, 2024 (HealthDay news) -- Medicare and Medicaid patients are less likely to get cutting-edge weight-loss drugs than people with private insurance are, a new study finds.

Medicaid accounted for less than 10% of semaglutide (Ozempic, Wegovy) prescription fills in 2023, researchers ...

Two new studies show how eager Americans are to obtain either safe, legitimate versions of Ozempic or counterfeit and potentially dangerous forms of the diabetes/weight-loss drug.

One study found U.S. prescriptions and refills of Ozempic (semaglutide) soari...

The boom in using GLP-1 drugs like Ozempic to treat obesity has resulted in a bust regarding the drugs’ original purpose, which was to treat type 2 diabetes, a new study finds. 

New prescriptions for these drugs have doubled among people who have obesity but not diabetes, investigators...

Nearly half of cancer deaths and 4 of 10 cases of cancer are linked to a person's lifestyle, a new study says.

Cigarette smoking remains the biggest cancer risk, contributing to 30% of cancer deaths and 20% of cancer cases, results show.

But excess body weight, drinking, lack of exercise, diet and skipping cancer-preventing vaccinations also increase a person's risk of developing or...

Three of four patients stop taking Ozempic or Wegovy two years after being prescribed the blockbuster drugs for weight loss, a new analysis shows.

Conducted by Prime Therapeutics and Magellan Rx Management (MRx), the review sifted through pharmacy and medical c...